KEGG   DRUG: Litgenprostucel-L
Entry
D10015                      Drug                                   
Name
Litgenprostucel-L (USAN);
CG8711
Efficacy
Antineoplastic
  Type
Cellular therapy product
Comment
Immunotherapy for the treatment of prostate cancer
One of two components of a prostate cancer cellular immunotherapy consisting of a prostate adenocarcinoma cell line, LNCaP, that has been modified to secrete Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) and irradiated to prevent tumor cell replication
Target
CSF2RA (GMCSFR, CD116) [HSA:1438] [KO:K05066]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04630  JAK-STAT signaling pathway
hsa05200  Pathways in cancer
Brite
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokine receptors
   CSF and other factor receptors
    CSF2RA (GMCSFR, CD116)
     D10015  Litgenprostucel-L (USAN)
Other DBs
PubChem: 135626736
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system